Price
Frequently asked questions
What is Evotec's market capitalization?
What is the Earnings Per Share (EPS) for Evotec?
What are the analyst ratings and target price for Evotec's stock?
What is Evotec's revenue over the trailing twelve months?
What is the EBITDA for Evotec?
What is the free cash flow of Evotec?
What is the 5-year beta of Evotec's stock?
How many employees does Evotec have, and what sector and industry does it belong to?
What is the free float of Evotec's shares?
Financials
Market Cap
$1.40B5Y beta
0.96EPS (TTM)
-$1.049Free Float
175.52MRevenue (TTM)
$858.38MEBITDA (TTM)
-$79.58MFree Cashflow (TTM)
-$267.48MPricing
Analyst Ratings
The price target is $23.48 and the stock is covered by 10 analysts.
Buy
8
Hold
2
Sell
0
Information
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
5,022
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker